Proteins from molecule to market
Novo Nordisk is a protein-based, focused healthcare company. We have refined our protein competencies over the past 80 years, and we have developed world class expertise in:
- Protein engineering using mutation, pegylation and acylation as well as genetic, enzymatic and chemical modification. Novo Nordisk has refined these techniques since it introduced insulin in 1923.
- Protein expression in E.coli, yeast, and mammalian cells. Novo Nordisk houses state-of-the-art facilities with capacities up to 160,000 L, including commercial scale production of mammalian cells.
- Protein formulation is a key factor in optimizing the interface between the complex protein molecule and its delivery system. Novo Nordisk continues to refine its protein formulation technology and masters half-life extension, sustained release, liquid formulations and, more recently, pulmonary formulations.
- Protein delivery systems. Novo Nordisk pioneered this area by introducing the NovoPen® insulin pen device in 1985. Since then Novo Nordisk has developed more than 20 injection systems, be it durable, pre-filled and cartridges.
We are committed to engineering proteins into safe and effective therapies, and also developing new and improved protein delivery systems for people relying on our products. Strategically, this is our route to further enhance user convenience and adherence to therapy. To this end R&D leverages a unique competence: developing proteins from molecule to market.
